Traumatic brain injuries (TBIs) affect 2.5 million Americans per year, and survivors of TBI can
develop long-term impairments in physical, cognitive, and psychosocial functions. Currently …

RNA interference (RNAi) has increased the possibility of restoring RNA drug targets for
cancer treatment. Small interfering RNA (siRNA) is a promising therapeutic RNAi tool that …

Inhibiting specific gene expression by short interfering RNA (siRNA) offers a new therapeutic
strategy to tackle many diseases, including cancer, metabolic disorders, and viral infections …

RNA interference holds the promise to knock down expression of every cancer gene. Both
academic laboratories and pharmaceutical companies have committed heavily on …

The application of RNA interference-based gene silencing technologies has the potential to
treat a variety of illness. Preclinical studies and some early clinical trials have already …

Recent successes in clinical trials have provided important proof of concept that small
interfering RNAs (siRNAs) indeed constitute a new promising class of therapeutics. Although …

Small interfering RNAs (siRNAs) silence the expression of specific target genes by
mediating RNA interference (RNAi) in mammalian cells. siRNAs have not only been widely …

RNA interference (RNAi) is an evolutionarily conserved process by which double-stranded
small interfering RNA (siRNA) induces sequence-specific, post-transcriptional gene …

Short interfering RNA (siRNA) functions directly in the cytoplasm, where it is assembled into
an RNA‐induced silencing complex (RISC). The localized delivery of siRNA to a specific site …

RNA interference (RNAi) is considered a highly specific approach for gene silencing and
holds tremendous potential for treatment of various pathologic conditions such as …